Vitamin A
Evidence Fact Sheet
Vitamin A (retinol/retinyl esters and provitamin A carotenoids) is a fat-soluble nutrient whose active metabolite retinoic acid regulates vision, epithelial barriers, immunity and cell differentiation via RAR/RXR receptors. Evidence is strongest in deficiency settings; high-dose preformed retinol is teratogenic and EFSA-authorized for several function claims.
Also known as: Retinol · Retinyl palmitate · Retinyl acetate · Pre-formed vitamin A · Vitamina A · Retinal · Retinoic acid · Vitamin A (as retinyl palmitate)
Overview
Vitamin A is a fat-soluble nutrient supplied either as preformed retinol/retinyl esters (animal sources, supplements) or provitamin A carotenoids such as beta-carotene. Retinol is oxidized to retinal (the visual pigment in rhodopsin) and to retinoic acid, which binds nuclear RAR/RXR receptors to regulate genes governing cell differentiation, epithelial/mucosal integrity and immune function. Typical research and supplemental doses fall around the dietary reference range (US RDA 700-900 mcg RAE/day; common supplemental 700-1500 mcg RAE/day), with WHO high-dose programs using intermittent 100,000-200,000 IU in deficient children; the US tolerable upper intake level is 3000 mcg RAE/day for preformed retinol only. It is GRAS in the US, carries six EFSA Article 13(1) function claims (vision, skin, mucous membranes, immune function, iron metabolism, cell specialisation), and is an authorized supplement constituent under ANVISA and China's health-food framework. Preformed vitamin A is teratogenic at high doses and contraindicated above label limits in pregnancy.
Mechanism of Action
Retinol oxidized to retinal (visual pigment 11-cis-retinal in rhodopsin) and to retinoic acid (gene-regulatory ligand) · Retinoic acid binds nuclear retinoic acid receptors (RAR-alpha/beta/gamma) and retinoid X receptors (RXR), regulating ~500 target genes including those for cell differentiation, immune function, and epithelial integrity · Maintains mucosal barrier integrity in respiratory, gastrointestinal, and urogenital epithelia via mucin synthesis and goblet cell differentiation · Required for normal photoreceptor function (rod and cone visual cycle) and dark adaptation · Modulates innate and adaptive immune responses including T-cell differentiation, dendritic cell function, and IgA production
Body systems: Skin & Connective Tissue · Vision · Immune System
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Vitamin A is not characterized as a treatment for any disease.
Child Morbidity and Mortality (Deficiency-Prone Populations)
Meta-analysis supported- RR 0.88 (0.83-0.93)all-cause mortality · high certainty
- RR 0.45 (0.30-0.69)measles incidence
In this Cochrane meta-analysis of 47 trials in roughly 1.2 million children aged 6 months to 5 years, vitamin A supplementation was associated with a 12% reduction in all-cause mortality (high-certainty evidence) and reduced incidence of measles and diarrhoea. These benefits are concentrated in vitamin-A-deficient, lower-income settings rather than well-nourished populations.
Reported effect: 12% reduction in all-cause mortality (RR 0.88, 95% CI 0.83 to 0.93; high-certainty); measles incidence RR 0.45 (95% CI 0.30 to 0.69); diarrhoea incidence RR 0.85 (95% CI 0.82 to 0.87)
“At longest follow-up, there was a 12% observed reduction in the risk of all-cause mortality for VAS compared with control using a fixed-effect model (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.83 to 0.93; high-certainty evidence). VAS reduced the incidence of measles (RR 0.45, 95% CI 0.30 to 0.69; 2 studies, 1,982 children; low-certainty evidence).”
Source: PMID 35294044 · Imdad 2022 · Cochrane Database Syst Rev
Iron Metabolism and Anaemia
Meta-analysis supported- 26%anaemia risk reduction
- WMD 6.61 µg/L (6.00-7.21)serum ferritin · pregnant/lactating
This systematic review and meta-analysis of 23 studies found that vitamin A supplementation reduced anaemia risk by 26% and raised haemoglobin, with a significant increase in serum ferritin in pregnant and lactating women. The effect was most apparent in individuals with low serum retinol, consistent with vitamin A's role in mobilizing iron from hepatic stores.
Reported effect: Anaemia risk reduced by 26%; serum ferritin increase in pregnant/lactating women WMD 6.61 µg/L (95% CI 6.00 to 7.21; p<0.001)
“VAS reduces the risk of anemia by 26% and raises hemoglobin levels, compared to non-treated group ... a significant increase in serum ferritin levels was observed in trials conducted with pregnant and lactating women (WMD 6.61 μg/L; 95% CI 6.00 to 7.21 μg/L; p < 0.001)”
Source: PMID 29336593 · Cunha 2019 · Crit Rev Food Sci Nutr
Iron Deficiency Prevalence in Children/Teenagers (Null Finding)
Null / no benefit Meta-analysis supported- RR 0.82 (0.60-1.12)iron deficiency · p=0.204
Within the same meta-analysis, vitamin A supplementation did NOT significantly change the prevalence of iron deficiency in trials of children and teenagers. This is an honest null result: vitamin A appears to support haemoglobin and ferritin but does not by itself resolve iron-deficiency status in younger populations.
Reported effect: No change in iron deficiency prevalence in children/teenagers (RR 0.82, 95% CI 0.60 to 1.12, p = 0.204)
“VAS did not alter the prevalence of iron deficiency among the clinical trials conducted with children and teenagers (RR 0.82, 95% CI 0.60 to 1.12, p = 0.204)”
Source: PMID 29336593 · Cunha 2019 · Crit Rev Food Sci Nutr
Age-Related Macular Degeneration Progression (AREDS Antioxidant Formula)
Meta-analysis supported- OR 0.72 (0.58-0.90)progression to late AMD
In this Cochrane systematic review of 26 RCTs (11,952 participants), the AREDS antioxidant multivitamin (vitamin C, vitamin E, beta-carotene and zinc) probably slowed progression to late age-related macular degeneration, with moderate-certainty evidence. Note this is a combination formula including beta-carotene (a provitamin A carotenoid), not preformed vitamin A alone.
Reported effect: Progression to late AMD odds ratio 0.72 (95% CI 0.58 to 0.90; 3 studies, 2445 participants; moderate-certainty); neovascular AMD OR 0.62 (95% CI 0.47 to 0.82)
“People taking antioxidant vitamins were less likely to progress to late AMD (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.90; 3 studies, 2445 participants; moderate-certainty evidence).”
Source: PMID 37702300 · Evans 2023 · Cochrane Database Syst Rev
Childhood Mortality in a Vitamin-A-Deficient Community (Landmark RCT)
RCT supported- 49%higher mortality in control villages
This landmark Indonesian community-randomized trial in 25,939 preschool children across 450 villages found mortality in control villages was 49% greater than in villages receiving periodic vitamin A supplements (p<0.05). The authors estimated supplementation could lower mortality by as much as 34% in vitamin-A-deficient populations, establishing the deficiency-correction paradigm.
Reported effect: Mortality in control villages (7.3 per 1000) 49% greater than in supplemented villages (4.9 per 1000), p<0.05; estimated mortality reduction up to 34%
“Among children aged 12-71 months at baseline, mortality in control villages (75/10 231, 7.3 per 1000) was 49% greater than in those where supplements were given (53/10 919, 4.9 per 1000) (p less than 0.05).”
Source: PMID 2871418 · Sommer 1986 · Lancet
Early Neonatal Vitamin a Supplementation and Infant Survival (Null Finding)
Null / no benefit Meta-analysis supported- RR 0.97 (0.89-1.06)6-month infant mortality
This individual-participant-data meta-analysis of 11 randomized trials in 163,567 infants found NO overall effect of early neonatal vitamin A dosing on infant survival through 6 months or 12 months. It is a prominent honest negative: a strategy that helps older deficient children did not translate to a neonatal mortality benefit, though some regional subgroups suggested context-dependent effects.
Reported effect: No effect on infant survival through 6 months (RR 0.97, 95% CI 0.89 to 1.06); 12-month mortality RR 1.00 (95% CI 0.93 to 1.08)
“Overall there was no effect of NVAS on infant survival through 6 (risk ratio (RR) 0.97; 95% CI 0.89 to 1.06).”
Source: PMID 30425075 · Neonatal Vitamin A Supplementation Evidence group 2019 · Arch Dis Child
High-Dose Beta-Carotene and Lung Cancer in Smokers (Safety Signal, Honest Negative)
Null / no benefit RCT supported- 18% (CI 3 to 36)higher lung cancer incidence
In the ATBC trial of 29,133 male smokers, beta-carotene 20 mg/day (a provitamin A carotenoid) UNEXPECTEDLY raised lung cancer incidence by 18% versus placebo. This is a critical safety boundary: high-dose beta-carotene supplementation is contraindicated in current and former heavy smokers, in whom it increased rather than reduced cancer risk.
Reported effect: 18% higher lung cancer incidence with beta-carotene (95% CI 3 to 36 percent) in male smokers
“Unexpectedly, we observed a higher incidence of lung cancer among the men who received beta carotene than among those who did not (change in incidence, 18 percent; 95 percent confidence interval, 3 to 36 percent).”
Source: PMID 8127329 · Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group 1994 · N Engl J Med
Dosage (research context · not a recommendation)
US IOM RDA: 900 mcg RAE/day adult men, 700 mcg RAE/day adult women (1300 mcg/day lactation). EFSA NDA PRI: 750 mcg RE/day adult men, 650 mcg RE/day adult women (700 mcg/day pregnancy, 1300 mcg/day lactation). EFSA NRV (labelling): 800 mcg RE. US IOM Tolerable Upper Intake Level (UL): 3000 mcg RAE/day adults (preformed retinol only; not applicable to provitamin A carotenoids). Common supplemental doses: 700-1500 mcg RAE/day. WHO high-dose supplementation programs use 100,000-200,000 IU intermittently in deficient children.
Regulatory Status · 4 Markets
- US · FDA
- United States (FDA): NO 21 CFR Part 101 Subpart E Significant Scientific Agreement (SSA) health claim exists for vitamin A. The SSA catalogue is limited to specific nutrient-disease pairs (calcium/osteoporosis, sodium/hypertension, dietary fat/cancer, saturated fat & cholesterol/CHD, fiber-grain products/cancer, fiber-fruits-vegetables/CHD, folate/NTDs, sugar alcohols/dental caries, soluble fiber/CHD, soy protein/CHD, plant sterol-stanol/CHD, fluoride/dental caries) — none of which involve vitamin A. Vitamin A in dietary supplements is governed by: (1) DSHEA §403(r)(6) structure/function claims under 21 CFR 101.93 with the mandatory disclaimer "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease."; (2) nutrient-content claims under 21 CFR 101.54 (e.g., "high in", "good source of vitamin A"); (3) labeling per 21 CFR 101.9 with %DV based on the 900 mcg RAE adult reference. No FDA Qualified Health Claim (QHC) for vitamin A as a standalone nutrient has been issued at the standalone-nutrient level. Pre-formed vitamin A teratogenicity warning per FDA UL of 3,000 mcg RAE/day required on supplements; pregnancy supplementation >10,000 IU/day contraindicated.
- EU · EFSA
- European Union (EFSA / Reg 432/2012): Six authorized Article 13(1) general-function health claims for vitamin A in the Annex to Commission Regulation (EU) No 432/2012 (CELEX:32012R0432) — normal iron metabolism, maintenance of normal mucous membranes, maintenance of normal skin, maintenance of normal vision, normal function of the immune system, role in the process of cell specialisation. All six share the standard condition: claim may be used only for food which is at least a source of vitamin A per the SOURCE OF [VITAMIN/MINERAL] reference in the Annex to Regulation (EC) No 1924/2006 (>=15% NRV per 100 g/100 mL or per portion; NRV = 800 mcg RE per Regulation (EU) No 1169/2011 Annex XIII). EFSA NDA Panel underlying opinion: EFSA Journal 2009;7(9):1221. No Article 14 disease-risk-reduction claim authorised for vitamin A.
- CN · China
- Listed in China's nutrient-supplement filing catalogue and approved as a food nutrition fortifier under GB 14880-2012; also a permitted health-food raw material. Health-food products may carry the supplement claim 'supplements vitamin A' and the function claim 'helps maintain dark-adaptation vision'; ordinary foods may not bear function claims. SAMR recognized.
- BR · ANVISA
- Brasil (ANVISA): Vitamina A é constituinte autorizado para suplementos alimentares conforme Instrução Normativa DC/ANVISA nº 28, de 26/07/2018 (Anexos I/II — lista de constituintes; Anexos III/IV — limites mínimos e máximos calculados como equivalente de atividade de retinol, RAE; Anexo V — alegações autorizadas). As alegações de propriedade funcional para vitamina A seguem o padrão "A vitamina A auxilia ..." (verbo "auxilia", não "contribui para"). NOTA DE SEGURANÇA: vitamina A pré-formada (retinol/ésteres de retinila) tem teratogenicidade em altas doses; UL adulto = 3.000 mcg RAE/dia; suplementação em gestantes >10.000 UI/dia contraindicada (advertência obrigatória conforme RDC 243/2018).
Authorized Claims
ANVISA — “A vitamina A auxilia na visão.” (IN 28/2018 Anexo V)
Safety
Pre-formed vitamin A (retinol / retinyl esters) is TERATOGENIC at high doses. Pregnancy supplementation >10,000 IU/day (>3000 mcg RAE/day) is associated with increased risk of birth defects (Rothman 1995 NEJM) and is contraindicated. UL of 3000 mcg RAE/day applies only to pre-formed vitamin A, not to provitamin A carotenoids (β-carotene). However, high-dose β-carotene supplementation (20-30 mg/day) in current and former heavy smokers was associated with INCREASED lung cancer incidence in the ATBC (Heinonen 1994 NEJM) and CARET (Omenn 1996 NEJM) trials and is contraindicated in this population. Chronic intake of pre-formed retinol above the UL may cause hypervitaminosis A (hepatotoxicity, intracranial pressure, bone loss). Hypothyroidism, renal/hepatic impairment, and alcohol use disorder may increase susceptibility to toxicity. Provitamin A (β-carotene from food) does not cause hypervitaminosis A but can cause reversible carotenodermia. Pregnancy: do not exceed 700 mcg RAE/day from supplements unless clinically directed; rely on dietary β-carotene rather than supplemental retinol for additional intake.
Related
Goals: skin-beauty · eye-protection · longevity-stack
Lifestyles: senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 35294044 · Imdad 2022 · Cochrane Database Syst Rev — Child Morbidity and Mortality (Deficiency-Prone Populations)
- PMID 29336593 · Cunha 2019 · Crit Rev Food Sci Nutr — Iron Metabolism and Anaemia
- PMID 37702300 · Evans 2023 · Cochrane Database Syst Rev — Age-Related Macular Degeneration Progression (AREDS Antioxidant Formula)
- PMID 2871418 · Sommer 1986 · Lancet — Childhood Mortality in a Vitamin-A-Deficient Community (Landmark RCT)
- PMID 30425075 · Neonatal Vitamin A Supplementation Evidence group 2019 · Arch Dis Child — Early Neonatal Vitamin a Supplementation and Infant Survival (Null Finding)
- PMID 8127329 · Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group 1994 · N Engl J Med — High-Dose Beta-Carotene and Lung Cancer in Smokers (Safety Signal, Honest Negative)
Frequently Asked Questions
1. Is vitamin A's mortality benefit seen in everyone, or only in deficient populations?
The strongest survival evidence comes from vitamin-A-deficient, lower-income settings. The Cochrane meta-analysis of 47 trials in about 1.2 million children found a 12% reduction in all-cause mortality (RR 0.88), and the landmark Sommer 1986 Indonesian trial of 25,939 children found 49% higher mortality in unsupplemented control villages. These findings reflect correction of deficiency and should not be generalized to well-nourished populations.
2. Does vitamin A help with anaemia and iron status?
A meta-analysis of 23 studies (Cunha 2019) reported that vitamin A supplementation reduced anaemia risk by 26%, raised haemoglobin, and increased serum ferritin in pregnant and lactating women (WMD 6.61 µg/L). Honest caveat from the same analysis: it did NOT significantly change iron-deficiency prevalence in children and teenagers (RR 0.82, 95% CI 0.60 to 1.12), so vitamin A supports iron handling but does not by itself resolve iron deficiency. This aligns with EFSA's authorized 'contributes to normal iron metabolism' function claim.
3. Are there situations where vitamin A or beta-carotene supplements were harmful?
Yes. In the ATBC trial of 29,133 male smokers, high-dose beta-carotene (a provitamin A carotenoid) raised lung cancer incidence by 18% versus placebo, so it is contraindicated in current and former heavy smokers. Separately, the individual-participant-data meta-analysis of 163,567 infants found early neonatal vitamin A dosing had no overall effect on infant survival (RR 0.97). Preformed vitamin A is also teratogenic at high doses, which is why supplements carry pregnancy warnings.
4. What is vitamin A and how does it work in the body?
Vitamin A is a fat-soluble nutrient available as preformed retinol/retinyl esters or as provitamin A carotenoids like beta-carotene. Retinol converts to retinal, the visual pigment used in rhodopsin, and to retinoic acid, which binds nuclear RAR/RXR receptors to regulate genes for cell differentiation, mucosal/epithelial integrity, and immune function. It carries six EFSA Article 13(1) function claims (vision, skin, mucous membranes, immune system, iron metabolism, cell specialisation) and is GRAS in the US, with a tolerable upper intake level of 3000 mcg RAE/day for preformed retinol.
Last evidence review: 2026-06-06